The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and
liposome containing formulations, and methods of using polyglutamated antifolates and
liposome containing formulations to treat hyerproliferative disorders (e.g.,
cancer) and disorders of the
immune system (e.g., an
autoimmune disease such as
rheumatoid arthritis).